Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors
Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors
About this item
Full title
Author / Creator
Publisher
Basel: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Basel: MDPI AG
Subjects
More information
Scope and Contents
Contents
The mutation-driven transformation of clinical anti-androgen drugs into agonists of the human androgen receptor (AR) represents a major challenge for the treatment of prostate cancer patients. To address this challenge, we have developed a novel class of inhibitors targeting the DNA-binding domain (DBD) of the receptor, which is distanced from the...
Alternative Titles
Full title
Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_4aa1ebf257e04f9f8d6c4c6190d87376
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_4aa1ebf257e04f9f8d6c4c6190d87376
Other Identifiers
ISSN
2073-4409
E-ISSN
2073-4409
DOI
10.3390/cells11182785
